The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Time course of skin toxicity (tox) secondary to erlotinib (E) therapy in patients (pts) with non-small cell lung cancer (NSCLC) enrolled in the SATURN study.
R. Perez-Soler
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
F. Cappuzzo
Consultant or Advisory Role - Roche
Honoraria - Roche
L. Leon
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
S. Wojtowicz-Praga
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech